Pfizer Inc. $PFE Shares Newly Bought by Leo Wealth LLC

Key Points

• Leo Wealth LLC purchased 60,136 Pfizer shares in the third quarter, worth approximately $1.715 million. Institutional investors collectively own 68.36% of Pfizer’s outstanding stock.
• Pfizer reported quarterly EPS of $0.77, beating estimates of $0.68, while revenue reached $15.03 billion. The company declared a quarterly dividend of $0.43 per share, representing a 5.8% annualized yield.
• Analysts maintain a consensus “Hold” rating with an average price target of $28.72, below the reported share price of $29.80. Recent pipeline developments include expanded FDA approval for TALZENNA plus XTANDI and Phase 2 results for Pfizer’s 25-valent pneumococcal vaccine candidate.

Leo Wealth LLC bought a new position in Pfizer Inc. (NYSE:PFE - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 60,136 shares of the biopharmaceutical company's stock, valued at approximately $1,715,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Retirement Wealth Solutions LLC boosted its stake in Pfizer by 144.6% in the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 509 shares during the period. Evolution Wealth Management Inc. grew its holdings in Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 566 shares in the last quarter. Keb Asset Management LLC bought a new stake in shares of Pfizer during the second quarter valued at about $26,000. Field & Main Bank bought a new stake in shares of Pfizer during the second quarter valued at about $27,000. Finally, Global Trust Asset Management LLC increased its position in shares of Pfizer by 126.7% during the first quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 650 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

NYSE:PFE opened at $29.80 on Tuesday. The firm has a market capitalization of $169.82 billion, a price-to-earnings ratio of 39.20, a P/E/G ratio of 2.04 and a beta of 0.32. Pfizer Inc. has a 52-week low of $23.62 and a 52-week high of $30.44. The stock has a fifty day moving average of $28.30 and a 200 day moving average of $26.67. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to analysts' expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The firm's revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts expect that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.8%. The ex-dividend date is Friday, November 6th. Pfizer's dividend payout ratio (DPR) is 226.32%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded approval of TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) for men with metastatic hormone-sensitive prostate cancer whose tumors have homologous recombination repair (HRR) gene mutations, including BRCA and non-BRCA mutations. Moving the treatment into an earlier stage of metastatic disease could enlarge the addressable patient population and support future sales growth. Pfizer's TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
• Positive Sentiment: Pfizer also reported Phase 2 results across serotypes for its 25-valent pneumococcal conjugate vaccine candidate, 25vPnC. The update adds visibility to the company’s vaccine pipeline, though the available report does not provide enough detail to assess the results’ commercial significance. Pfizer announces results across serotypes in Phase 2 study of 25vPnC
• Neutral Sentiment: Pfizer’s shares have gained about 29.7% over the past year and are near their 52-week high, prompting discussion over whether the valuation is ahead of the company’s earnings growth. Investors may require further pipeline or operating improvements to justify additional gains. Pfizer Stock Looks Above Fair Value As 30% Run Continues
• Neutral Sentiment: Pfizer was relatively resilient while Moderna and BioNTech declined amid disappointment over cancer-vaccine trial data. The comparison may offer some support for PFE, but it does not directly change Pfizer’s fundamentals. Moderna Tumbles as Cancer Vaccine Selloff Deepens
• Negative Sentiment: Broader healthcare stocks traded lower, creating sector-level pressure on Pfizer. Separately, an experimental Pfizer lung-cancer drug showed a survival benefit in some patients despite a failed trial, leaving its development outlook uncertain rather than providing a clear catalyst. Healthcare Stocks Softer Monday

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on PFE. Cantor Fitzgerald increased their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Thursday, October 8th. HSBC boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a "hold" rating in a research note on Thursday, September 10th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, October 13th. Scotiabank upped their target price on shares of Pfizer from $30.00 to $33.00 and gave the stock an "outperform" rating in a report on Tuesday, October 6th. Finally, BMO Capital Markets lowered their target price on shares of Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a research note on Monday, July 13th. Five research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $28.72.

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company's portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.